Status:
RECRUITING
The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer
Lead Sponsor:
Nuvance Health
Conditions:
Pancreatic Cancer Stage III
Pancreatic Cancer Stage IV
Eligibility:
All Genders
18+ years
Brief Summary
Aberrant miRNA production has been linked to a wide range of human cancers and shown to play important roles in their genesis and growth. These miRNA can be detected in the blood and tumors of patient...
Detailed Description
Specific aims of the study include: 1. To obtain serum samples from patients with newly diagnosed pancreatic cancer at baseline before treatment and monthly throughout treatment. 2. To analyze the mi...
Eligibility Criteria
Inclusion
- Have biopsy proven adenocarcinoma of the pancreas
- Have initially inoperable disease, classified as either locally advanced or metastatic disease
- Recurrent disease after a Whipple procedure is allowed
- Patients who are able to undergo resection after neoadjuvant therapy will continue to be followed after resection
- Have radiographically measurable disease
- Have an ECOG performance status of 2 or less
- Be willing to contribute the required information and specimens
- Provide written signed consent to participate
Exclusion
- Having received prior anti-cancer treatments for metastatic pancreatic cancer
- Concurrently receiving systemic therapy for another cancer except androgen deprivation therapy for stable/controlled prostate cancer
- Presence of other active cancer except for: adequately treated local basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for \>1 year prior to start of trial. Other adequately treated Stage 1 or 2 cancer currently in complete remission, or any other cancer that has been in complete remission for \> 5 years is allowable
Key Trial Info
Start Date :
April 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2027
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04406831
Start Date
April 1 2015
End Date
April 1 2027
Last Update
April 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nuvance Health
Norwalk, Connecticut, United States, 06856